Shopping Cart
Remove All
Your shopping cart is currently empty
CDK12-IN-E9
🥰Excellent
Catalog No. T14915Cas No. 2020052-55-3
CDK12-IN-E9 is a cell cycle protein kinase (CDK) inhibitor with anticancer and antitumor activity that can be used in the study of breast cancer.
CDK12-IN-E9
🥰Excellent
Catalog No. T14915Cas No. 2020052-55-3
CDK12-IN-E9 is a cell cycle protein kinase (CDK) inhibitor with anticancer and antitumor activity that can be used in the study of breast cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $132 | - | In Stock | |
| 5 mg | $328 | - | In Stock | |
| 10 mg | $496 | - | In Stock | |
| 25 mg | $873 | - | In Stock | |
| 50 mg | $1,180 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $363 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | CDK12-IN-E9 is a cell cycle protein kinase (CDK) inhibitor with anticancer and antitumor activity that can be used in the study of breast cancer. |
| Targets&IC50 | CDK2-CyclinA:932 nM, CDK7-CyclinH-MNAT1:1210 nM, CDK9-CyclinT1:23.9 nM |
| In vitro | CDK12-IN-E9 treatment of Kelly, LAN5, SK-N-BE2, PC-9, NCI-H82, and NCI-H3122 cells after 72 hours of action in the concentration range of 10 nM to 10 μM showed significant antiproliferative activity against THZ1R neuroblastoma and lung cancer cells, with IC50 values ranging from 8 to 40 nM. After 6 hours of action in the concentration range of 0 to 3000 nM, CDK12-IN-E9 treatment of Kelly, PC-9, and NCI-H82 cells induced a dose-dependent decrease in phosphorylated and total RNAPII accompanied by a decrease in MYC and MCL1 expression in THZ1R neuroblastoma and lung cancer models. In addition, CDK12-IN-E9 increased PARP cleavage and elevated the proportion of sub-G1 phase cells in THZ1R lung cancer cells, whereas it was more likely to cause G2/M phase block in neuroblastoma cells after 24 hours of exposure. [1] |
| Molecular Weight | 434.53 |
| Formula | C24H30N6O2 |
| Cas No. | 2020052-55-3 |
| Smiles | C(C)C1=C2N(C(NC3=CC(NC(C=C)=O)=CC=C3)=CC(=N2)N4[C@H](CCO)CCCC4)N=C1 |
| Relative Density. | 1.28 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (230.13 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (9.21 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy CDK12-IN-E9 | purchase CDK12-IN-E9 | CDK12-IN-E9 cost | order CDK12-IN-E9 | CDK12-IN-E9 chemical structure | CDK12-IN-E9 in vitro | CDK12-IN-E9 formula | CDK12-IN-E9 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.